---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010792"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:11:11.209094+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics gets Nasdaq extension to Sept 25, 2023; must meet $2.5M equity rule

## Summary
- Received 180-day extension from Nasdaq; must regain compliance with $2.5M stockholders' equity by Sept 25, 2023.
- Reported stockholders' equity of ($5.545M) as of Dec 31, 2022, below requirement.
- Failure to demonstrate compliance by Sept 25 may lead to delisting; company intends to take measures.
- Delisting could reduce liquidity, market price, and access to equity markets.

## SEC filing metadata
- accession: 0001558370-23-010792
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/0001558370-23-010792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/agrx-20230602x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010792
- JSON: https://secwatch.observer/filing/0001558370-23-010792.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010792.txt

## Key facts
- Listing & Compliance Notices
  AGILE THERAPEUTICS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders’
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837023010792/0001558370-23-010792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.